Profile
John Bondo Hansen was the founder of Sound Biotechnology, Inc. (founded in 2008) where he held the title of Chief Scientific Officer in 2010.
He was also the founder of Konticon Consulting, Inc. (founded in 2008) where he served as the Managing Director.
Additionally, Dr. Hansen is the founder of Conrig Pharma ApS (founded in 2010) and currently holds the title of Chief Executive Officer & Director.
Dr. Hansen is also the founder of Contera Pharma ApS.
Dr. Hansen's current job is as a Senior Advisor at Pcovery ApS.
His former job positions include being a Director at Aurigene Discovery Technologies Ltd.
and serving as the Vice President-Diabetes Research Unit at Novo Nordisk A from 2002 to 2008.
Dr. Hansen obtained a doctorate degree from the University of Copenhagen.
John Bondo Hansen active positions
| Companies | Position | Start |
|---|---|---|
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Conrig Pharma ApS
 Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Founder | 2010-12-19 |
Former positions of John Bondo Hansen
| Companies | Position | End |
|---|---|---|
| Sound Biotechnology, Inc. | Founder | 2009-12-31 |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | - |
| Konticon Consulting, Inc. | Chief Executive Officer | - |
Aurigene Discovery Technologies Ltd.
 Aurigene Discovery Technologies Ltd. BiotechnologyHealth Technology Aurigene Discovery Technologies Ltd. operates as biotechnology company. It offers research services such as integrated research and stand-alone research. The company is headquartered in Bangalore, India. | Director/Board Member | - |
Training of John Bondo Hansen
| University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Private companies | 6 |
|---|---|
Aurigene Discovery Technologies Ltd.
Aurigene Discovery Technologies Ltd. BiotechnologyHealth Technology Aurigene Discovery Technologies Ltd. operates as biotechnology company. It offers research services such as integrated research and stand-alone research. The company is headquartered in Bangalore, India. | Health Technology |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Sound Biotechnology, Inc. | |
| Konticon Consulting, Inc. | |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Conrig Pharma ApS
Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Stock Market
- Insiders
- John Bondo Hansen